A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

NCT02111564 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

12024

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure
Respiratory Insufficiency
Stroke Acute
Infectious Diseases
Rheumatic Diseases

Interventions

DRUG: Rivaroxaban, 10 mg
DRUG: Rivaroxaban, 7.5 mg
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC

Collaborators

[object Object]